Journal of the National Cancer Institute Advance Access originally published online on September 9, 2008
JNCI Journal of the National Cancer Institute 2008 100(18):1335-1336; doi:10.1093/jnci/djn278
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
CORRESPONDENCE |
Response: Re: Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial
Affiliations of authors: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (TER, AN); Division of Research, Kaiser Permanente, Oakland, CA (LAH)
Correspondence to: Thomas E. Rohan, MBBS, PhD, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461 (e-mail: rohan{at}aecom.yu.edu).
We thank Drs Wood and Cline for their interest in our paper. With respect to the first piece of information that they requested, an erratum was published [J Natl Cancer Inst 2008;100(10):754] in which the 579 eligible sections that they refer to were corrected to be 520 sections. These 520 eligible sections were from 478 women (because some women had more than one biopsy during the course of the trial). Of the latter, 269 (56.3%) were in the conjugated equine estrogen (CEE) group, of whom 155 (57.6%) had evidence of benign proliferative breast disease; the remaining 209 (43.7%) women were in the placebo group, and 77 (36.8%) of these women had benign proliferative breast disease. We note further that the hazard ratio (HR) for the association between CEE and risk of nonproliferative breast disease was 0.95 (95% confidence interval [CI] = 0.72 to 1.24, P = .684), suggesting that the effect of CEE was specific to benign proliferative breast disease and was not due to differences in sampling intensity.
With respect to the second piece of information, we would like to clarify that in the published journal article, line 4 of table 2, "atypical hyperplasia," is a subset of the combined category listed in line 3 of table 2. There, we stated that "Risk of atypical hyperplasia alone was not altered by the intervention, but analysis of this effect was based on only 18 cases in the intervention group and 15 in the placebo group (HR = 1.12, 95% CI = 0.53 to 2.40)."
Related Correspondence
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 1335.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||